Literature DB >> 32931422

Testosterone and prostate health: Have the paradigms truly shifted?

Alvaro Morales1, D Robert Siemens1.   

Abstract

Entities:  

Year:  2020        PMID： 32931422      PMCID： PMC7402689          DOI： 10.5489/cuaj.6549

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN： 1911-6470            Impact factor:   1.862


× No keyword cloud information.
  46 in total

1.  Plasma organochlorine levels and prostate cancer risk.

Authors:  Kristan J Aronson; James W L Wilson; Meghan Hamel; Wienta Diarsvitri; Wenli Fan; Christy Woolcott; Jeremy P W Heaton; J Curtis Nickel; Andrew Macneily; Alvara Morales
Journal:  J Expo Sci Environ Epidemiol       Date:  2009-06-10       Impact factor: 5.563

Review 2.  Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline.

Authors:  Shalender Bhasin; Glenn R Cunningham; Frances J Hayes; Alvin M Matsumoto; Peter J Snyder; Ronald S Swerdloff; Victor M Montori
Journal:  J Clin Endocrinol Metab       Date:  2010-06       Impact factor: 5.958

3.  Hormonal predictors of prostate cancer: a meta-analysis.

Authors:  T Shaneyfelt; R Husein; G Bubley; C S Mantzoros
Journal:  J Clin Oncol       Date:  2000-02       Impact factor: 44.544

4.  A prospective study to examine the association of the urinary and fecal microbiota with prostate cancer diagnosis after transrectal biopsy of the prostate using 16sRNA gene analysis.

Authors:  Shaheen Alanee; Ahmed El-Zawahry; Danuta Dynda; Ali Dabaja; Kevin McVary; Mallory Karr; Andrea Braundmeier-Fleming
Journal:  Prostate       Date:  2018-08-16       Impact factor: 4.104

5.  Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial.

Authors:  Leonard S Marks; Norman A Mazer; Elahe Mostaghel; David L Hess; Frederick J Dorey; Jonathan I Epstein; Robert W Veltri; Danil V Makarov; Alan W Partin; David G Bostwick; Maria Luz Macairan; Peter S Nelson
Journal:  JAMA       Date:  2006-11-15       Impact factor: 56.272

6.  Bipolar androgen therapy: the rationale for rapid cycling of supraphysiologic androgen/ablation in men with castration resistant prostate cancer.

Authors:  Samuel R Denmeade; John T Isaacs
Journal:  Prostate       Date:  2010-10-01       Impact factor: 4.104

7.  Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia.

Authors:  Ernani Luis Rhoden; Abraham Morgentaler
Journal:  J Urol       Date:  2003-12       Impact factor: 7.450

Review 8.  Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth.

Authors:  Abraham Morgentaler; Abdulmaged M Traish
Journal:  Eur Urol       Date:  2008-09-24       Impact factor: 20.096

Review 9.  Dietary Carcinogens and DNA Adducts in Prostate Cancer.

Authors:  Medjda Bellamri; Robert J Turesky
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

Review 10.  Testosterone therapy and prostate cancer.

Authors:  Alexander W Pastuszak; Katherine M Rodriguez; Taylor M Nguyen; Mohit Khera
Journal:  Transl Androl Urol       Date:  2016-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.